Reply:
Matthew Hoare, Graeme Alexander – 27 March 2009
Insulin resistance and platelet count/spleen diameter ratio: Two simple, easy‐to‐get tests for predicting esophageal varices in cirrhosis
Xiaohua Li, Kaichun Wu, Daiming Fan – 27 March 2009
Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential
Anna Moles, Núria Tarrats, José C. Fernández‐Checa, Montserrat Marí – 27 March 2009 – Cathepsins have been best characterized in tumorigenesis and cell death and implicated in liver fibrosis; however, whether cathepsins directly regulate hepatic stellate cell (HSC) activation and proliferation, hence modulating their fibrogenic potential, is largely unknown. Here, we show that expression of cathepsin B (CtsB) and cathepsin D (CtsD) is negligible in quiescent HSCs but parallels the increase of α‐smooth muscle actin and transforming growth factor‐β during in vitro mouse HSC activation.
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B
Maurizia Rossana Brunetto, Francesco Moriconi, Ferruccio Bonino, George K. K.
The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen–positive and hepatitis B e antigen–negative hepatitis B virus strains
Samad Amini‐Bavil‐Olyaee, Ulf Herbers, Julie Sheldon, Tom Luedde, Christian Trautwein, Frank Tacke – 27 March 2009 – Tenofovir is a new effective treatment option for patients with chronic hepatitis B, but could be potentially hampered by mutations in the hepatitis B virus (HBV) polymerase conferring drug resistance. Drug resistance may occur preferentially if long‐term administration is required, for example, in patients with hepatitis B e antigen (HBeAg)‐negative HBV infection bearing precore (PC) and basal core promoter (BCP) mutations.
Histological changes in hepatitis C virus antibody–positive, hepatitis C virus RNA–negative subjects suggest persistent virus infection
Isabelle Moreau, Elizabeth Kenny‐Walsh, Orla Crosbie, Liam J. Fanning – 27 March 2009
Reply:
Salvatore Petta, Calogero Cammà, Antonio Craxì – 27 March 2009
Frequent in‐frame somatic deletions activate gp130 in inflammatory hepatocellular tumors
M. M. Spannbauer, C. Trautwein – 27 March 2009
Advanced chronic hepatitis C: How to handle if you cannot halt?
Wolf Peter Hofmann, Stefan Zeuzem – 27 March 2009
Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA‐21 up‐regulation in hepatocytes
Manlio Vinciguerra, Antonino Sgroi, Christelle Veyrat‐Durebex, Laura Rubbia‐Brandt, Leo H. Buhler, Michelangelo Foti – 27 March 2009 – Phosphatase and tensin homolog (PTEN) is a regulator of phosphoinositide 3‐kinase signaling and an important tumor suppressor mutated/deleted in human cancers. PTEN deletion in the liver leads to insulin resistance, steatosis, inflammation, and cancer.